01 / DESIGN
What was studied?
Researchers screened drug-response scores against transcriptomic and clinical datasets from primary and recurrent glioma cohorts.
02 / FINDINGS
What did the researchers report?
The computational analysis prioritized sermorelin and linked predicted sensitivity with cell-cycle and immune-related signatures.
03 / LIMITS
How should it be interpreted?
Patients in these datasets were not shown to benefit from sermorelin administration. Predicted drug sensitivity is hypothesis-generating and requires experimental and clinical validation.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.